Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The oral, anti-inflammatory drug colchicine can prevent complications and hospitalizations in nonhospitalized patients newly diagnosed with COVID-19, according to a press release from the ColCORONA trial investigators. After 1 month of therapy, there was a 21% risk reduction in the primary
0 Comments
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3
0 Comments
U.S. President Joe Biden speaks about his administration’s plans to respond to the economic crisis during a coronavirus disease (COVID-19) response event in the State Dining Room at the White House in Washington, January 22, 2021. Jonathan Ernst | Reuters President Joe Biden has painted a bleak picture of the nation’s coronavirus outbreak in his
0 Comments
Many college students fully recover from infectious mononucleosis (which is almost always caused by Epstein-Barr virus) within 1-6 weeks, but some go on to develop chronic fatigue syndrome, also called myalgic encephalomyelitis (ME/CFS). A longitudinal study from DePaul University and Northwestern University followed 4,501 college students to examine risk factors that may trigger longer illness.
0 Comments
Low doses of the recombinant T-cell growth factor interleukin 2 (IL-2, aldesleukin, Proleukin) were well tolerated among patients with moderate-to-severe ulcerative colitis in a small 8-week study, with only one patient being withdrawn because of a dose-limiting toxicity, a researcher reported. There also were preliminary suggestions of efficacy, with 38.4% of the 26 patients enrolled
0 Comments
Researchers have developed a new classification of cognitive function for patients with multiple sclerosis (MS) that is based on the identification of five cognitive phenotypes. Dr Ermelinda De Meo “This is the first time there has been a complete categorization of cognitive profiles in MS patients,” lead author Ermelinda De Meo, MD, IRCCS San Raffaele
0 Comments
London, UK — 16 January 2021 GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid cancers being presented today at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). Study results (abstract #9) showed a 38.7% objective response rate (ORR) (N=106, 95% CI;
0 Comments
FDA Approves Cabenuva (cabotegravir and rilpivirine) Long-Acting Injectable HIV Treatment and Vocabria (cabotegravir) Oral HIV Treatment London, 21 January 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first
0 Comments
Schools are closing again in response to surging levels of COVID-19 infection, but staging randomized trials when students eventually return could help to clarify uncertainties around when we should send children back to the classroom, according to a new study. Experts say that school reopening policies currently lack a rigorous evidence base – leading to
0 Comments
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Full-dose anticoagulation was superior to low, prophylactic doses in reducing the need for vital organ support such as ventilation in moderately ill patients hospitalized for COVID-19, according to a report released today by the National Institutes of Health (NIH). “This is
0 Comments
Blood tests to screen for amyloid-beta could cut the need for PET scans in half in asymptomatic Alzheimer’s research trials, a British cohort study suggested. To find 100 amyloid PET-positive, dementia-free older adults from a population with similar amyloid PET positivity prevalence to the study cohort without plasma screening, 543 PET scans would need to
0 Comments
In a study published by JAMA Psychiatry methamphetamine overdose deaths rose dramatically over an eight-year period from 2011-2018. The study, conducted by the National Institute on Drug Abuse, determined that while the country was focused on the opioid crisis, a methamphetamine crisis was developing “quietly and actively.” The death rate from methamphetamine overdoses rose from
0 Comments
Most people recover from the depression associated with a hip fracture in about a year as they return to normal activities, researchers find. Physicians can help by encouraging these patients to stay in contact with friends and family, said senior author Timothy Bhattacharyya, MD, head of the Clinical and Investigative Orthopedics Surgery Unit at the
0 Comments
Letters, syllables, words and sentences–spatially arranged sets of symbols that acquire meaning when we read them. But is there an area and cognitive mechanism in our brain that is specifically devoted to reading? Probably not; written language is too much of a recent invention for the brain to have developed structures specifically dedicated to it.
0 Comments
BOSTON–(BUSINESS WIRE)–December 21, 2020 — Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that are responsive to
0 Comments
Johnson & Johnson board member Dr. Mark McClellan told CNBC that “if the clinical trial works out,” the company could significantly increase the nation’s Covid vaccine supply availability within the coming weeks.  “I do know that J&J is making a very large supply, going all out with its production, both here in the U.S. and
0 Comments
Since the coronavirus pandemic hit the US last year, cleaning supplies have been a hot commodity. Disinfectant wipes and sprays have been in short supply as people scramble for the old standbys of home disinfecting. But a recent EPA approval now permits a new weapon into the arsenal: a thyme-derived disinfectant spray from Laboratoire M2,
0 Comments
Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. About 20 states across the country have detected the more transmissible B.1.1.7 SARS-CoV-2 variant to date. Given the unknowns of the emerging situation, experts with the Infectious Diseases Society of America (IDSA) addressed vaccine effectiveness, how well equipped the United States is to
0 Comments
The FDA approved the first long-acting injectable therapy for people living with HIV, the agency said late Thursday. Injectable cabotegravir-rilpivirine (Cabenuva) was approved for people with HIV who are virologically suppressed on a stable antiviral regimen with no history of treatment failure. It is administered once a month. “Having this treatment available for some patients
0 Comments
In a time-stratified, case-crossover study, exposure to both large and small particulate matter, as well as to nitrogen dioxide, was significantly associated with increased odds of death from myocardial infarction (MI). Investigators found “consistent evidence” that short-term exposure to particulate matter with an aerodynamic diameter of 2.5 μm or smaller (PM2.5), particulate matter with an aerodynamic
0 Comments
New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01. The results were published
0 Comments
FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization
0 Comments